Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

BETHESDA, Md., April 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.

MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth clinical program in Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the treatment of haematological cancers.

"BiTE antibodies enable the patients' own T cells to very efficiently eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer of Micromet, "In various experimental tumor models, we have demonstrated the high therapeutic potential of EpCAM-specific BiTE antibodies, and we are now looking forward to determining the safety and the therapeutic potential of MT110 in patients."

"Having obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological cancers, we are excited about exploring the potential of MT110 in treating solid tumors," comments Carsten Reinhardt, Chief Medical Officer of Micromet. "Based on its unique mode of ac
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is ... patients. Available in both small (6mm) and ... Fixation System from Zimmer is a modular system that offers ... XtraFix System allows surgeons to eliminate steps, as ... resulting in saved time, costs and overall team effort. ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
(Date:3/27/2015)... 2015  Johnson & Johnson (NYSE: JNJ ) will ... Time) on Thursday, April 23, 2015, from the State Theatre ... Investors and other interested parties may access the live audio ... www.jnj.com and clicking on the webcast icon. ... made available a few hours after the live meeting concludes. ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... in Cellular and Molecular Medicine at Boston Children,s Hospital ... developed a molecular delivery platform that overcomes one of the ... cancer: Making sure the treatment gets to the right place ... PhD, of the PCMM/IDI, and a former fellow from her ...
... 18, 2012  Genetic testing to determine a more accurate initial ... remains rare, but is often done for inappropriate patients, according ... pharmacy benefit manager (PBM). The study will be presented on ... (AMCP),s 24th Annual Meeting & Expo in San Francisco. ...
Cached Medicine Technology:Packaging therapeutic RNAs for targeted treatment of breast cancer 2Packaging therapeutic RNAs for targeted treatment of breast cancer 3Packaging therapeutic RNAs for targeted treatment of breast cancer 4Genetic testing for new warfarin patients is rare, but often inappropriate 2
(Date:3/28/2015)... Coffee could not only perk you up in the morning ... have found. , They found that those who drank coffee ... fight gum disease. Does coffee, then, help fight gum disease? ... Goldman School of Dental Medicine explored in a study ... of Periodontology. , “This is the first long-term study of ...
(Date:3/28/2015)... 2015 "Necrorun" was featured on NewsWatch ... look at the latest and coolest applications on the ... host of NewsWatch and technology expert, conducted the app ... entertaining endless runner game with knights, nature, and peasants. ... in 2009, according to Eurogamer. The popularity of these ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... ... Discovery Health, - PREGNANT MAN Premieres Tuesday, November 18, at ... November 19, at 10:00 PM ET/PT -, SILVER SPRING, Md., Nov. ... Thomas Beatie tells the definitive story of,his first pregnancy this Tuesday on ...
... DALLAS, Nov. 13 As Sandy Mullen and ... they were,caring for in the eating disorders unit ... the seemingly successful treatment of a,patient,s primary addiction ... After reviewing hundreds of cases, Mullen, RN, an ...
... 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), a ... cardiovascular disease, today announced financial results,for the three and ... loss for the three months ended September 30, 2008 ... million, or $0.35 per,share, for the same period of ...
... learned might one day lead to vaccine that works , , ... develop an AIDS vaccine has failed, but researchers report that ... one more effective. , "It,s raised a whole new set ... answer to get us to a successful vaccine," said Dr. ...
... Corp. (Nasdaq:,HMSY) today announced that it will present at ... November 18-19, 2008 at The New,York Palace Hotel., ... at 11:00 am,ET., HMS Holdings Corp. (Nasdaq: ... and program integrity services for government,healthcare programs. The company,s ...
... N.J., Nov. 13 Medco Health,Solutions, Inc. (NYSE: ... Jr., and other members of the Medco senior leadership ... financial results and,business outlook to analysts and investors during ... titled "Inventing World-Class Healthcare,Solutions," is scheduled to begin at ...
Cached Medicine News:Health News:Pregnant Man Thomas Beatie Is Pregnant Again 2Health News:Pregnant Man Thomas Beatie Is Pregnant Again 3Health News:Dallas Addiction Specialists Reveal Discovery in New Book 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Medco to Webcast 2008 Analyst Day Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: